Journal article
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Blood, Vol.111(7), pp.3751-3759
Neoplasia
04/01/2008
DOI: 10.1182/blood-2007-07-102186
PMCID: PMC2275031
PMID: 18216297
Abstract
The V617F activating point mutation in Jak2 is associated with a proportion of myeloproliferative disorders. In normal hematopoietic cells, Jak2 signals only when associated with a growth factor receptor, such as the erythropoietin receptor (EpoR). We sought to identify the molecular requirements for activation of Jak2V617F by introducing a point mutation in the FERM domain (Y114A), required for receptor binding. Whereas BaF3.EpoR cells are readily transformed by Jak2V617F to Epo independence, we found that the addition of the FERM domain mutation blocked transformation and the induction of reactive oxygen species. Further, while cells expressing Jak2V617F had constitutive activation of STAT5, cells expressing Jak2V617F/Y114A did not, suggesting that signaling is defective at a very proximal level. In addition, expression of the Myc and Pim proto-oncogenes by Jak2V617F was found to be FERM domain dependent. An inducible constitutively active STAT5 mutant expressed in BaF3 cells was sufficient to induce Myc and Pim. Finally, the FERM domain in Jak2V617F was also required for abnormal hematopoiesis in transduced primary murine fetal liver cells. Overall, our results suggest that constitutive activation of Jak2 requires an intact FERM domain for a transforming phenotype, and is necessary for activation of the major target of Jak2, STAT5.
Details
- Title: Subtitle
- The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
- Creators
- Gerlinde Wernig - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MAJeffrey R Gonneville - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MABrian J Crowley - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MAMargret S Rodrigues - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MAMamatha M Reddy - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MAHeidi E Hudon - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MAChristoph Walz - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MAAndreas Reiter - III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, GermanyKlaus Podar - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MAYohan Royer - Ludwig Institute for Cancer Research, Brussels, Belgium; andStefan N Constantinescu - Ludwig Institute for Cancer Research, Brussels, Belgium; andMichael H Tomasson - Department of Medicine, Washington University School of Medicine, St Louis, MOJames D Griffin - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MAD. Gary Gilliland - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MAMartin Sattler - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.111(7), pp.3751-3759
- Publisher
- American Society of Hematology
- Series
- Neoplasia
- DOI
- 10.1182/blood-2007-07-102186
- PMID
- 18216297
- PMCID
- PMC2275031
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 04/01/2008
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094572402771
Metrics
19 Record Views